Related Experiment Video
Updated: Jul 10, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Nephropathic cystinosis: late complications of a multisystemic disease
Galina Nesterova1, William Gahl
1Section on Human Biochemical Genetics, Human Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-1851, USA.
Insights
Cystinosis is a rare genetic disorder causing cystine buildup in lysosomes, leading to kidney failure. Oral cysteamine therapy significantly improves lifespan and prevents severe complications in affected individuals.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Cystinosis is a rare autosomal recessive lysosomal storage disease.
- It results from impaired cystine export from lysosomes, leading to systemic accumulation.
- Nephropathic cystinosis presents with severe renal and systemic manifestations.
Observation:
- End-stage renal disease (ESRD) and Fanconi syndrome are hallmark features, historically causing significant mortality.
- Prior to cysteamine therapy and transplantation, lifespan was limited to approximately 10 years.
- Despite improved survival into the fifth decade, non-renal complications remain a major concern.
Findings:
- Cystine-depleting therapy with oral cysteamine has dramatically improved patient outcomes.
- Early diagnosis and treatment are crucial for managing systemic involvement.
- Cysteamine therapy plays a vital role in preventing long-term complications.
Implications:
- Oral cysteamine therapy represents a breakthrough in managing cystinosis, extending patient lifespan.
- Understanding the natural history and systemic effects is key to comprehensive patient care.
- Further research into non-renal manifestations and novel therapies is warranted.
Abstract:
Cystinosis is a rare autosomal recessive disorder due to impaired transport of cystine out of cellular lysosomes. Its estimated incidence is 1 in 100,000 live births. End-stage renal disease (ESRD) is the most prominent feature of cystinosis and, along with dehydration and electrolyte imbalance due to renal tubular Fanconi syndrome, has accounted for the bulk of deaths from this disorder. Prior to renal transplantation and cystine-depleting therapy with cysteamine for children with nephropathic cystinosis, their lifespan was approximately 10 years. Now, cystinotic patients have survived through their fifth decade, but the unremitting accumulation of cystine has created significant non-renal morbidity and mortality. In this article we review the classic presentation of nephropathic cystinosis and the natural history, diagnosis, and treatment of the disorder's systemic involvement. We also emphasize the role of oral cysteamine therapy in preventing the late complications of cystinosis.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrons
Chronic Kidney Disease II: Clinical Manifestations
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
